Hamdy Ahmed MD 4
4 · CURIS INC · Filed Mar 18, 2026
Research Summary
AI-generated summary of this filing
Curis (CRIS) CMO Hamdy Ahmed Receives Equity Awards
What Happened
- Hamdy Ahmed, M.D., Chief Medical Officer of Curis, Inc. (CRIS), was reported as receiving four equity awards/other acquisitions on March 17, 2026: one grant of 50 derivative shares and three grants of 66,667 derivative shares (total = 200,051 derivative shares). The Form 4 lists these as awards/acquisitions (code A) with no per-share cash price reported on the face of the form.
- Footnotes clarify these securities involve Series B Convertible Preferred Stock and attached Series A, B and C warrants. Each purchased “Security” was sold at $1,000 per Security to the reporting person (footnote F2). The Series B preferred stock automatically converts into common stock at 1,333.33 common shares per preferred share at 5:00 p.m. ET on March 20, 2026 (subject to limits) (footnote F1).
Key Details
- Transaction date: March 17, 2026; Form filed March 18, 2026 (timely).
- Reported grants: 50; 66,667; 66,667; 66,667 — total 200,051 derivative shares.
- Price on Form 4: N/A. Footnote F2: each Security was sold at $1,000 per Security to the reporting person.
- Conversion/exercise notes:
- Series B Preferred converts to 1,333.33 common shares per preferred on March 20, 2026 (F1).
- Series A and Series C warrants became immediately exercisable on March 17, 2026 (F3, F5).
- Series B warrants are immediately exercisable but have special termination and potential exercise-price reset tied to a clinical milestone (F4).
- Shares owned after transaction: not disclosed in the supplied summary of the filing.
Context
- These entries report derivative acquisitions/awards rather than an open-market purchase or sale of common stock. For retail investors, the key points are the imminent conversion feature (potentially large increase in common shares if conversion occurs) and the attached warrants with varying exercisability and termination terms.
- This is an award/acquisition filing (not a sale). The filing appears timely (filed the next day). As always, derivative awards and automatic conversions can dilute existing holders and should be considered alongside company disclosures about conversion mechanics and beneficial ownership limits.
Insider Transaction Report
Form 4
CURIS INCCRIS
Transactions
- Award
Series B Convertible Preferred Stock
[F1][F2]2026-03-17+50→ 50 total→ Common Stock (66,667 underlying) - Award
Series A Warrant (right to buy)
[F2][F3]2026-03-17+66,667→ 66,667 totalExercise: $0.75Exp: 2031-01-08→ Common Stock (66,667 underlying) - Award
Series B Warrant (right to buy)
[F4][F2]2026-03-17+66,667→ 66,667 totalExercise: $0.75→ Common Stock (66,667 underlying) - Award
Series C Warrant (right to buy)
[F2][F5]2026-03-17+66,667→ 66,667 totalExercise: $0.75Exp: 2027-07-08→ Common Stock (66,667 underlying)
Footnotes (5)
- [F1]Each share of Series B Convertible Non-Redeemable Preferred Stock ("Series B Preferred Stock") automatically converts into 1,333.33 shares of Common Stock for no additional consideration at 5 p.m. Eastern Time on March 20, 2026, subject to the terms of the Certificate of Designations, Preferences and Rights of Series B Convertible Non-Redeemable Preferred Stock of Curis, Inc. (the "Certificate of Designations") and subject to the applicable Beneficial Ownership Limitations (as defined in the Certificate of Designations).
- [F2]Each share of Series B Preferred Stock was sold together with a Series A Warrant to purchase 1,333.33 shares of Common Stock, a Series B Warrant to purchase 1,333.33 shares of Common Stock and a Series C Warrant to purchase 1,333.33 shares of Common Stock (collectively, a "Security"). The Securities were sold at a purchase price of $1,000.00 per Security to the Reporting Person.
- [F3]Each Series A Warrant became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series A Warrant) on March 17, 2026.
- [F4]The Series B Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing (each as defined in the Series B Warrant) and will terminate upon the 30th calendar day following date on which the Company publicly announces that the fifth patient has been dosed in the Company's Phase 2 clinical trial of emavusertib in combination with an approved Bruton Tyrosine Kinase Inhibitor in chronic lymphocytic leukemia ("Initial Termination Date"). If the closing sale price of the Company's Common Stock at the Initial Termination Date is below $0.75 (the "Exercise Price"), such Exercise Price will be reset to the closing sale price of the Company's Common Stock on the Initial Termination Date (provided that the Exercise Price will not be reduced to less than 50% of the initial Exercise Price) and the Initial Termination Date will be extended an additional 30 days.
- [F5]The Series C Warrants became immediately exercisable following the receipt of Requisite Stockholder Approval and the Certificate of Amendment Filing on March 17, 2026.
Signature
/s/ Diantha Duvall, Attorney-in-fact|2026-03-18